Abbott Laboratories

Insider trust buys 9,900 Abbott shares amid 18% loss, citing strong diagnostics pipeline and FDA clearance; experts see long‑term confidence despite volatility.

Abbott CEO’s $2 M buy‑the‑dip in a 28% slump shows confidence that diagnostics, vascular and nutrition lines can revive stock value after earnings miss.